October 13, 2016
(Washington, D.C.)— Amid the debate on escalating drug prices, a new report estimates that by implementing the full range of...
Filter by:
Specialty Benefit Design
Filter by Year:Clear Filters- Press Releases
- Biosimilars
- Drug Abuse Prevention
- Drug Adherence Programs
- Drug Cost Management
- Drug Coupons & Assistance Programs
- Drug Coverage Mandates
- Drug Price Negotiations & Rebates
- Employers, Unions, & Insurers
- FEHBP Program
- Formulary Design
- Fraud, Waste, & Abuse
- Generic Drug Utilization
- Health Insurance Marketplace (ACA)
- Home Delivery of Drugs
- Mark Merritt
- Medicaid
- Medicare Part D
- Patient Cost Sharing
- Pharmacy Networks
- Pharmacy Reimbursement & Contracting
- REMS Management
- Specialty Benefit Design
- Specialty Pharmacies
- Specialty Pharmacy Networks
- TRICARE
- Value & Outcomes-Based Contracting
PCMA Statement on Oversight Committee Hearing on EpiPen Price Hikes
September 21, 2016
(Washington, D.C.) —Pharmaceutical Care Management Association (PCMA) President and CEO Mark Merritt issued the following statement on today’s House Committee...
September 20, 2016
A new report, “Comparison of Hepatitis C Treatment Costs,” shows Hepatitis C drug prices, specifically negotiated by pharmacy benefit managers...